What You Should Know:
– A new cancer treatment and research era is dawning in Japan with the launch of LC-SCRUM-CD (Lung Cancer Genome Screening Project for Individualized Medicine – Clinical Development).
– The nationwide clinical trial network is a collaborative effort between the National Cancer Center (NCC), Precision Medicine Asia Co., Ltd. (PREMIA), and Paradigm Health Inc. (Paradigm).
Building on LC-SCRUM-Asia’s Foundation
LC-SCRUM-CD expands upon the existing LC-SCRUM-Asia network, which comprises over 150 hospitals and boasts extensive cancer genomic screening capabilities.This foundation will be instrumental in driving clinical trials focused on precision medicine, tailoring treatments to individual patients based on their genetic makeup.
A Collaborative Approach to Advance Precision Medicine
The collaboration between NCC, PREMIA, and Paradigm brings together expertise and resources. NCCHE (National Cancer Center Hospital East), a leader in clinical trials in Japan, will play a pivotal role in the network. PREMIA, with its expertise in data management, will oversee the network’s data platform, integrating vast amounts of genetic and clinical data to efficiently identify potential clinical trial candidates.
Paradigm’s Innovative Approach to Clinical Trials
Paradigm Health brings its innovative, end-to-end clinical trial platform to the network. This platform is designed to streamline clinical trial processes, reducing the burden on physicians and hospital staff while expanding patient trial access. Paradigm’s success in working with rural and community-based health systems in the US will inform the design and operation of LC-SCRUM-CD, ensuring broader reach and accessibility.
Benefits of the LC-SCRUM-CD Network
- Increased Efficiency: Streamlined processes and workflows will make it more efficient for pharmaceutical companies to conduct clinical trials in Japan.
- Expanded Access: More patients across the LC-SCRUM-Asia network will have access to a wider range of clinical trial options.
- Reduced Burden: Paradigm’s platform will significantly reduce the time and burden on clinical staff involved in trials.
- Improved Outcomes: By promoting precision medicine and expanding access to clinical trials, LC-SCRUM-CD has the potential to significantly improve patient outcomes.
“NCCHE is a world-renowned hospital and research institution, where patients from across Japan come to receive care,” Dr Goto, a deputy director and the chief of department of thoracic oncology at NCCHE and the representative of LC-SCRUM-Asia, said. “Working with our partners at PREMIA and Paradigm, we will fully utilize this expertise in clinical trial operations, allowing all patients who are taking part in LC-SCRUM-Asia to benefit from personalized access to the breadth of clinical trials being run by global biopharmaceutical sponsors at the same time as the US.”
